Xu Yaping, Director of the Department, Discipline Leader, Doctor of Oncology, Chief Physician. Professor at Tongji University School of Medicine, Doctoral Supervisor, Provincial and Ministerial High-Level Innovative Talent in Health. She studied under the renowned domestic oncologist, Academician Yu Jinning, and served as a visiting scholar at the University of Michigan Cancer Center in the United States. She possesses advanced concepts and extensive experience in precise radiotherapy for lung tumors, combined treatments for locally advanced lung cancer (squamous cell carcinoma, adenocarcinoma, small cell carcinoma) involving radiotherapy, chemotherapy, targeted drugs, and immunotherapy, as well as the prevention, diagnosis, and management of radiation pneumonitis. She has long been engaged in the early diagnosis of lung tumors, precise radiotherapy (X-knife, SBRT, IMRT, IGRT), and multidisciplinary comprehensive treatment primarily based on radiotherapy. She is one of the earliest experts in China to promote SBRT and IGRT technologies for lung cancer treatment. In 2012, she organized the first national continuing education workshop on SBRT/IGRT for thoracic tumors, which received high praise from domestic peers. Multiple research achievements in precise radiotherapy for non-small cell lung cancer have been published in top domestic journals for tumor radiotherapy (Chinese Journal of Radiation Oncology series) and internationally renowned journals (Lung Cancer, IJROBP, TLCR, etc.). She has served as editor-in-chief and deputy editor-in-chief of monographs such as *Strategies for Thoracic Tumor Radiotherapy* and *Essentials and Clinical Practice of Thoracic Tumor Radiotherapy*; as chief translator of monographs including *Theory and Practice of Image-Guided Radiotherapy for Lung Cancer*, *Latest Advances in Tumor Radiotherapy: IMRT, IGRT, and SBRT*, and *Radiotherapy Treatment Planning Strategies*; and as a contributing author to the *Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2020 Edition)*, the first national *Chinese Expert Consensus on Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer*, and the *CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2020 Edition)*. Currently, she holds concurrent positions including Council Member of the Shanghai Anti-Cancer Association, Standing Committee Member of the Targeted Therapy and Immunotherapy Professional Committee of the Shanghai Anti-Cancer Association, Vice Chairperson of the Shanghai Branch of the Radioimmunology Working Committee of the Chinese Radiation Therapy Oncology Group (CRTOG), Standing Committee Member of the CSCO Non-Small Cell Lung Cancer Professional Committee, Standing Committee Member of the CSCO Translational Medicine Professional Committee, Standing Committee Member of the CRTOG Radiotherapy Professional Committee, Standing Committee Member of the Multidisciplinary Diagnosis and Treatment Professional Committee of the Chinese Medical Doctor Association, Vice Chairperson of the CRTOG Lung Cancer Working Committee, Member of the Lung Cancer Group of the Radiotherapy Professional Committee of the Chinese Medical Association, Member of the SBRT Group of the Radiotherapy Professional Committee of the Chinese Medical Doctor Association, Member of the Expert Database for the National Science and Technology Award, Editorial Board Member of *Translational Lung Cancer Research*, and Reviewer for *Cancer Biology & Medicine*. She has long been engaged in research on precise radiotherapy for lung tumors (X-knife, SBRT, IMRT, IGRT) and combined radiotherapy and immunotherapy for lung tumors. She has published over 100 academic papers, including more than 40 SCI-indexed papers. She has presented academic exchanges at international conferences such as WCLC, ASCO, ASTRO, ESMO, and ISDE on multiple occasions, including over 40 oral presentations and poster sessions. She has led 2 projects funded by the National Natural Science Foundation of China and over 10 other scientific research projects at provincial, ministerial, university, and bureau levels. She has served as the lead or sub-center PI for more than 30 multicenter clinical studies. As the project lead, she received the first prize of the 6th "Shanghai Anti-Cancer Science and Technology Award" in 2020 for "Establishment and Promotion of Stereotactic Radiotherapy Technology for Non-Small Cell Lung Cancer" (ranked first); as a project participant, she received the second prize of the 2019 National Science and Technology Progress Award for "Key Technology Research and Promotion of Precision Diagnosis and Treatment for Lung Cancer" (ranked fifth); and she has participated in or led over 10 other scientific research achievements that have received awards, including the Ministry of Education Science and Technology Award, the Chinese Anti-Cancer Association Science and Technology Award, the Provincial Science and Technology Progress Award, and the Provincial Natural Science Academic Award.